Hyperion Therapeutics (HPTX) Adds Daniel G. Welch to its Board of Directors
Tweet
Share
E-mailGet Alerts HPTX Hot Sheet
Join SI Premium – FREE
Hyperion Therapeutics (Nasdaq: HPTX) has named Daniel G. Welch to its Board of Directors. Mr. Welch currently serves as Chairman, Chief Executive Officer and President of InterMune, Inc. (Nasdaq: ITMN), a public biotechnology company based in Brisbane, California.
Mr. Welch has more than 30 years of experience in the biotechnology and pharmaceutical industries. Prior to InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., from 2002 to 2003.
Mr. Welch has more than 30 years of experience in the biotechnology and pharmaceutical industries. Prior to InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., from 2002 to 2003.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boeing names Ryan Shedd as new SVP and controller
- Qnity Electronics names Ken Rizvi as CFO, effective October 1
- AEye grants 125,000 RSUs to new chief revenue officer
Create E-mail Alert Related Categories
Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
